Could a Pill for This Common Condition Also Be Good for Your Heart? Scientists Are Finding Out

Tadalafil is one of the most widely prescribed drugs for erectile dysfunction, but recent research is pushing the conversation far beyond sexual health. An August 17 report from NPR highlighted how scientists, clinicians and telehealth companies are now examining whether the medication could also play a role in cardiovascular prevention. What is clear so far is that interest is rising; what remains unsettled is whether the drug itself is responsible for the better outcomes seen in large patient datasets.

Why tadalafil is getting fresh attention from heart researchers

Tadalafil belongs to a class of medicines called PDE-5 inhibitors, which also includes sildenafil, the drug sold as Viagra. These medications relax smooth muscle and widen blood vessels, which is why they are used for erectile dysfunction and, in some cases, pulmonary hypertension. Researchers say that same mechanism has made tadalafil a serious subject of discussion in preventive cardiology, according to NPR’s August 17 report.

Some of the strongest attention comes from large observational studies. A 2024 paper in Clinical Cardiology led by Dr. Robert Kloner examined more than 8,000 men with erectile dysfunction and found tadalafil exposure was associated with a 55% lower rate of cardiovascular death and a 44% lower rate of all-cause mortality during the study period. A separate large analysis involving more than 500,000 patients, as described by NPR, linked tadalafil use to a 32% lower risk of dementia along with lower mortality.

Those numbers have fueled discussion in medical and wellness circles because tadalafil is already generic and widely available. But the research cited by NPR and in the published studies is retrospective and observational, meaning it can show association rather than proof of cause. That distinction is central to how cardiologists are interpreting the data.

What experts say is known, and what is still unproven

The most important point for patients is that tadalafil is not approved by the U.S. Food and Drug Administration to prevent heart attack, stroke or death. Doctors interviewed by NPR said cardiologists are not routinely recommending it for those purposes, even as some specialists view the data as notable. Dr. Steve Nissen of the Cleveland Clinic told NPR that without randomized controlled trial evidence, broad preventive use is hard to justify.

At the same time, some medical groups are beginning to discuss narrower use cases. NPR reported that the Princeton Consensus Panel, a group focused on men’s sexual function and cardiovascular health, recently reached consensus language that low-dose tadalafil is “appropriate” for a subset of men at elevated risk of cardiovascular disease because of plaque buildup in the arteries, according to panel co-chair Dr. Martin Miner. NPR also reported that the panel’s formal recommendations have not yet been published.

That leaves several open questions. Researchers have not yet established whether the apparent benefits come directly from the drug, from differences in the men who seek treatment, or from other factors not fully captured in claims data. Experts also told NPR that tadalafil has been less thoroughly studied in women, so the evidence base is not the same across sexes.

What this means for patients as the evidence develops

For now, the practical takeaway is cautious interest rather than a change in standard care. Tadalafil has a long safety record in approved uses, and prior safety analyses published in PubMed have not found an increased rate of major cardiovascular adverse events in clinical trial data. That safety profile is one reason the drug is being discussed seriously by some researchers instead of dismissed outright.

Still, the gap between “promising” and “proven” remains large. NIH’s DREAM study found that sildenafil and tadalafil did not reduce the risk of Alzheimer’s and related dementias in a Medicare-based analysis, showing that not all research points in the same direction. That mixed picture is why specialists continue to call for prospective, randomized trials before any broader preventive claims are adopted.

For patients, that means tadalafil remains a medication for its approved indications unless a physician recommends it for another reason. The current evidence suggests a signal worth studying, and some clinicians see enough potential to keep the debate moving, but the scientific standard for routine heart-protection use has not yet been met.